NO20055026D0 - Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse - Google Patents

Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse

Info

Publication number
NO20055026D0
NO20055026D0 NO20055026A NO20055026A NO20055026D0 NO 20055026 D0 NO20055026 D0 NO 20055026D0 NO 20055026 A NO20055026 A NO 20055026A NO 20055026 A NO20055026 A NO 20055026A NO 20055026 D0 NO20055026 D0 NO 20055026D0
Authority
NO
Norway
Prior art keywords
indolone
processes
preparation
acetamide derivatives
acetamide
Prior art date
Application number
NO20055026A
Other languages
English (en)
Other versions
NO20055026L (no
Inventor
Benoit Kenda
Jean-Philippe Starck
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO20055026D0 publication Critical patent/NO20055026D0/no
Publication of NO20055026L publication Critical patent/NO20055026L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20055026A 2003-03-31 2005-10-28 Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse NO20055026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03007214 2003-03-31
PCT/EP2004/002691 WO2004087658A1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses

Publications (2)

Publication Number Publication Date
NO20055026D0 true NO20055026D0 (no) 2005-10-28
NO20055026L NO20055026L (no) 2005-12-22

Family

ID=33104041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055026A NO20055026L (no) 2003-03-31 2005-10-28 Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse

Country Status (19)

Country Link
US (2) US7645887B2 (no)
EP (1) EP1620399B1 (no)
JP (1) JP2006522041A (no)
KR (1) KR20050119186A (no)
CN (1) CN100364973C (no)
AR (1) AR043959A1 (no)
AT (1) ATE482193T1 (no)
AU (1) AU2004226288A1 (no)
BR (1) BRPI0408863A (no)
CA (1) CA2520568A1 (no)
DE (1) DE602004029245D1 (no)
ES (1) ES2353461T3 (no)
HK (1) HK1089768A1 (no)
MX (1) MXPA05009089A (no)
NO (1) NO20055026L (no)
RU (1) RU2005131317A (no)
TW (1) TW200508197A (no)
WO (1) WO2004087658A1 (no)
ZA (1) ZA200507231B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
AU2005214258A1 (en) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
ATE482194T1 (de) 2004-07-22 2010-10-15 Ucb Pharma Sa Indolonderivate, verfahren zu deren herstellung und deren anwendungen
WO2006118265A1 (ja) 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
EP2308870A3 (en) * 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
TW200801011A (en) 2006-02-07 2008-01-01 Astrazeneca Ab New compounds II
BRPI0710487A2 (pt) * 2006-04-12 2012-06-05 Merck & Co Inc composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitácel do mesmo e, método para tratar ou controlar a epilepsia e a dor e para o tratamento ou prevenção de um distúrbio do sono em um paciente.
WO2008133933A1 (en) * 2007-04-26 2008-11-06 Trustees Of Columbia University In The City Of New York Methods, systems, and compositions for treating or ameliorating the effects of a non-congenital hypertonia
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
EP2212293A4 (en) * 2007-10-24 2010-12-01 Merck Sharp & Dohme ANTAGONISTS OF T-TYPE CALCIUM CHANNELS BASED ON HETEROCYCLIC AMIDE
BRPI0818244A2 (pt) * 2007-10-24 2015-06-16 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
CN102227217A (zh) 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
CN107540597A (zh) * 2017-09-22 2018-01-05 苏州大学 N‑乙酰二甲胺基吲哚‑2‑酮衍生物的制备方法
US20210214359A1 (en) * 2018-05-29 2021-07-15 New York University Compounds and Methods for Treating Bacterial Infections
KR102669101B1 (ko) * 2021-08-10 2024-05-27 충북대학교 산학협력단 신규한 옥소인돌린 기반 아세토히드라지드 및 이를 유효성분으로 포함하는 항암제 조성물
CN114874127B (zh) * 2022-05-23 2023-06-09 中国药科大学 一种二氟羰基化吲哚酮类化合物的制备方法
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064910D1 (en) 1979-06-12 1983-10-27 Fujisawa Pharmaceutical Co 2-oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
JPS5697268A (en) * 1979-12-28 1981-08-05 Fujisawa Pharmaceut Co Ltd Lower alkanoic acid derivative, salt and preparation thereof and preventing agent and remedy for diabetic complication containing the same as active constituent
SU841264A1 (ru) * 1980-02-20 1995-11-10 Научно-исследовательский институт фармакологии АМН СССР Амид-2-оксо-1-индолинуксусной кислоты, обладающий противосудорожной активностью
DE3413572A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Oxindol-verbindungen zur behandlung der epilepsie
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
DK288287A (da) * 1986-06-09 1987-12-10 Pfizer Heterocycliske forbindelser samt farmaceutiske praeparater til behandling af allergiske eller inflammatoriske tilstande
JPH0195766A (ja) 1987-10-08 1989-04-13 Tamanoisu Kk 無蒸煮アルコール醪からの食酢の製造法
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
CA2036307C (en) 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
BR9200951A (pt) * 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
SE9302080D0 (sv) * 1993-06-16 1993-06-16 Ab Astra New compounds
JPH07304736A (ja) * 1994-05-10 1995-11-21 Kyowa Hakko Kogyo Co Ltd インドール誘導体
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
FR2738818B1 (fr) * 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2002514162A (ja) * 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
JPH1095766A (ja) * 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
AU2002213204A1 (en) * 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
AU2004222383B2 (en) * 2003-03-14 2009-10-01 Merck Sharp & Dohme Corp. Bicyclic anilide spirohydantoin CGRP receptor antagonists
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
ATE482194T1 (de) 2004-07-22 2010-10-15 Ucb Pharma Sa Indolonderivate, verfahren zu deren herstellung und deren anwendungen

Also Published As

Publication number Publication date
ES2353461T3 (es) 2011-03-02
US7964593B2 (en) 2011-06-21
US7645887B2 (en) 2010-01-12
KR20050119186A (ko) 2005-12-20
TW200508197A (en) 2005-03-01
AR043959A1 (es) 2005-08-17
EP1620399B1 (en) 2010-09-22
MXPA05009089A (es) 2005-11-17
ATE482193T1 (de) 2010-10-15
EP1620399A1 (en) 2006-02-01
BRPI0408863A (pt) 2006-04-11
US20100069375A1 (en) 2010-03-18
JP2006522041A (ja) 2006-09-28
AU2004226288A1 (en) 2004-10-14
DE602004029245D1 (de) 2010-11-04
CA2520568A1 (en) 2004-10-14
CN1768036A (zh) 2006-05-03
WO2004087658A1 (en) 2004-10-14
US20070043038A1 (en) 2007-02-22
ZA200507231B (en) 2006-11-29
NO20055026L (no) 2005-12-22
CN100364973C (zh) 2008-01-30
HK1089768A1 (en) 2006-12-08
RU2005131317A (ru) 2006-02-27

Similar Documents

Publication Publication Date Title
NO20055026D0 (no) Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse
NO20024281D0 (no) Indolderivater, fremgangsmåte for fremstilling av de samme og anvendelse derav
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
NO20053771D0 (no) Ringromsfluider og fremgangsmater for plassering av de samme
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20045064L (no) Indol-, azaindol- og beslektede heterocykliske 4-alkenyl-piperidin-amider
IS7079A (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
NO20054709D0 (no) Sammenfoyningssystem og anvendelse av dette
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20055204D0 (no) Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
ZA200800438B (en) N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and use thereof
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DK1912644T3 (da) N-(arylalkyl)-1h-pyrrolopyridin-2-carboxamid-derivater, fremstilling deraf og terapeutisk anvendelse deraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application